Metastatic Nasopharyngeal Carcinoma

To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.

Trial Details

NCT ID
NCT06886347
Phase
PHASE1
Sponsor
Chen Xiaozhong
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Penplimab Injection
  • Antitinib Hydrochloride Capsules
  • Gemcitabine
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • The participants voluntarily signed an informed consent form.
  • Age of ≥ 18 years and ≤ 75 years at the time of enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • xpected survival of ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →